Drugs in MeSH Category Hypolipidemic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	SIMVASTATIN	simvastatin	TABLET;ORAL	090383-002	Sep 16, 2011	AB	RX	No	No
Lupin	FENOFIBRATE	fenofibrate	TABLET;ORAL	204019-001	Aug 17, 2015	AB	RX	No	No
Pfizer	FLAVORED COLESTID	colestipol hydrochloride	GRANULE;ORAL	017563-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-003	Jul 28, 1997		DISCN	Yes	No

Hypolipidemic Agents Market Dynamics and Patent Landscape

Last updated: July 31, 2026

The hypolipidemic-agent market is shifting from mature statins and generic ezetimibe toward branded LDL-lowering therapies with longer patent lives, higher prices, and injectable delivery. Statins remain the volume base, while PCSK9 antibodies, inclisiran, bempedoic acid, and combination products drive branded revenue. Patent risk is highest for older oral products and emerging for biologic and RNA-based therapies as long-duration formulation, manufacturing, and method-of-use patents accumulate.

What drugs are included in the NLM MeSH class Hypolipidemic Agents?

The MeSH category includes drugs that reduce serum lipids or modify lipoprotein metabolism. Commercially important subgroups are:

Subclass	Representative drugs	Primary target or mechanism	Market status
Statins	Atorvastatin, rosuvastatin, simvastatin, pravastatin	HMG-CoA reductase inhibition	Predominantly generic
Cholesterol-absorption inhibitors	Ezetimibe	NPC1L1 inhibition	Generic; branded combinations remain
PCSK9 monoclonal antibodies	Evolocumab, alirocumab	PCSK9 inhibition	Branded biologics
ATP-citrate lyase inhibitor	Bempedoic acid	ACL inhibition	Branded oral product and combinations
siRNA therapy	Inclisiran	PCSK9 mRNA silencing	Branded injectable
Fibrates	Fenofibrate, gemfibrozil	PPAR-alpha activation	Generic
Bile-acid sequestrants	Colesevelam, cholestyramine	Intestinal bile-acid binding	Generic or authorized generic
Omega-3 products	Icosapent ethyl, omega-3-acid ethyl esters	Triglyceride reduction and cardiovascular-risk modification	Mixed generic and branded
Combination products	Ezetimibe/rosuvastatin, bempedoic acid/ezetimibe, statin combinations	Multiple lipid pathways	Mixed patent and generic exposure

The commercial center of gravity has moved from LDL reduction through statins to residual-risk treatment in patients who cannot reach target levels with statins alone.

Which hypolipidemic drugs generate the largest commercial exposure?

Statins generate the greatest prescription volume, but most revenue is generic. Branded revenue is concentrated in PCSK9 therapies, inclisiran, bempedoic-acid products, and icosapent ethyl.

Product	Active ingredient	Company	Administration	Principal commercial position
Repatha	Evolocumab	Amgen	Subcutaneous injection	Established PCSK9 antibody with broad cardiovascular-risk positioning
Praluent	Alirocumab	Sanofi/Regeneron	Subcutaneous injection	Competes directly with Repatha
Leqvio	Inclisiran	Novartis	Subcutaneous injection twice initially, then every six months	Long-interval PCSK9 silencing therapy
Nexletol	Bempedoic acid	Esperion	Oral tablet	LDL reduction for statin-intolerant or inadequately controlled patients
Nexlizet	Bempedoic acid/ezetimibe	Esperion	Oral tablet	Dual-mechanism oral therapy
Vascepa	Icosapent ethyl	Amarin	Oral capsule	Triglyceride reduction and cardiovascular-risk reduction
Zetia	Ezetimibe	Merck originator; generic manufacturers	Oral tablet	Generic core product; combination products retain commercial value

Amgen reported approximately $1.7 billion in 2023 Repatha sales, while Novartis reported approximately $180 million in 2023 Leqvio sales. Esperion reported approximately $187 million in 2023 net product sales for Nexletol and Nexlizet combined. Amarin reported approximately $248 million in 2023 Vascepa revenue.[1-4]

The key market distinction is access. Statins and ezetimibe are low-cost, guideline-established therapies. PCSK9 antibodies and inclisiran face prior authorization, specialty-pharmacy requirements, and payer scrutiny. Bempedoic acid occupies an oral alternative position, particularly for statin-intolerant patients.

What patents protect Repatha and evolocumab?

Repatha is protected by a layered biologic patent estate covering the antibody, antigen-binding sequences, formulations, dosing, and manufacturing.

Patent family or issue	Patent holder	Subject matter	Reported expiration profile
Evolocumab antibody and binding patents	Amgen	Anti-PCSK9 antibodies and binding regions	Core patents extend into the mid-2020s
Formulation and delivery patents	Amgen	Stable liquid formulations and prefilled delivery systems	Generally later than early composition claims
Method-of-use patents	Amgen	LDL reduction and cardiovascular-risk reduction	Claim scope depends on indication and statutory validity
Manufacturing patents	Amgen	Cell culture, purification, and antibody production	Can extend beyond core composition claims

Amgen has pursued patent litigation against biosimilar applicants and other parties involving PCSK9 antibody patents. The practical risk is greater than the expiration of a single composition patent because biosimilar applicants must address multiple patents, regulatory exclusivity, manufacturing controls, and interchangeability economics.

The FDA Purple Book lists biologic exclusivity and biosimilar information, while patent disputes are tracked through federal court dockets and the FDA’s litigation-related regulatory records.[5] Repatha has no FDA-approved biosimilar as of the latest publicly available product listings through 2024.

When does Repatha lose exclusivity?

The first meaningful loss-of-exclusivity window is controlled by surviving valid patents rather than by the 12-year biologic reference-product exclusivity period alone. Repatha’s biologic exclusivity period has expired, but commercial biosimilar entry depends on patent resolution and FDA approval.

Potential entry is more likely to occur through a negotiated settlement or an at-risk launch after patent litigation than through automatic entry on a single expiration date. The principal competitive threat is a follow-on biologic, not a conventional small-molecule generic.

What patents protect Praluent and alirocumab?

Praluent has composition, antibody-sequence, formulation, dosing, and method-of-use patents associated with Regeneron and Sanofi.

Protection category	Strategic effect
Anti-PCSK9 antibody claims	Protect the active biologic molecule
Epitope and binding claims	Create additional barriers around antibody function
Formulation claims	Protect concentration, stabilizers, and injectable presentation
Dosing claims	Support label-specific treatment regimens
Manufacturing claims	Increase complexity for biosimilar applicants

Praluent and Repatha have faced extensive patent litigation involving PCSK9 antibodies. The most important market issue has been whether a biosimilar or competing antibody can enter without infringing surviving claims. No FDA-approved Praluent biosimilar was listed through 2024.

How does Praluent compare with Repatha?

Factor	Repatha	Praluent
Active ingredient	Evolocumab	Alirocumab
Target	PCSK9	PCSK9
Modality	Fully human monoclonal antibody	Fully human monoclonal antibody
Dosing	Monthly or every two weeks, depending on product and indication	Every two weeks or monthly, depending on regimen
Market position	Larger commercial scale	Direct competitor
Patent risk	Amgen composition, formulation, and manufacturing estate	Regeneron/Sanofi composition, formulation, and use estate
Follow-on risk	Biosimilar risk after patent resolution	Biosimilar risk after patent resolution

Clinical differentiation is limited because both therapies produce substantial LDL-C reductions. Payer contracting, injection logistics, physician preference, and net price are often more important than molecular differentiation.

What patents protect Leqvio and inclisiran?

Leqvio is a chemically modified small interfering RNA administered by subcutaneous injection. Its patent estate differs from antibody estates because it can cover the siRNA sequence, chemical modifications, conjugation chemistry, formulation, delivery, dosing, and manufacturing.

Patent category	Likely protected subject matter
Composition patents	Inclisiran sequence and chemically modified siRNA
Conjugate patents	GalNAc or related liver-targeting conjugation
Formulation patents	Injectable liquid composition and stability
Dosing patents	Twice-yearly maintenance administration
Method-of-use patents	LDL-C lowering and cardiovascular-risk populations
Manufacturing patents	Oligonucleotide synthesis, purification, and conjugation

Novartis acquired global rights to inclisiran from The Medicines Company in a transaction valued at up to approximately $9.7 billion, including upfront and contingent consideration.[6] That transaction established Novartis as the principal commercial patent holder and licensee for the product.

When does Leqvio lose exclusivity?

Leqvio’s earliest commercial barriers are expected to come from composition and conjugation patents with expiration dates generally extending into the 2030s, while later patents may cover dosing, formulations, and manufacturing. The exact entry date will depend on the surviving claims, patent-term adjustments, pediatric extensions, and any settlement with an applicant.

Inclisiran has no established biosimilar market. A future competitor could pursue a biosimilar-like biologic pathway or another abbreviated route, but oligonucleotide comparability, conjugation consistency, clinical pharmacology, and manufacturing controls create higher barriers than those faced by conventional generics.

What patents protect Nexletol and Nexlizet?

Bempedoic acid is protected primarily through small-molecule composition, formulation, combination, and method-of-use patents.

Product	Main patent risk
Nexletol	Bempedoic acid composition, formulation, dosing, and cardiovascular-risk-reduction claims
Nexlizet	Bempedoic acid plus ezetimibe combination claims and formulation claims
Generic bempedoic acid	Paragraph IV challenge to listed Orange Book patents
Generic combination product	Separate challenge to combination and formulation patents

Esperion has reported patent protection for bempedoic acid products extending into the early 2040s for certain patents, although the effective protection period depends on patent validity and the scope of challenged claims.[3]

How strong is the bempedoic-acid patent estate?

The estate is commercially meaningful because it combines:

• A differentiated active ingredient for patients unable to tolerate adequate statin doses.
• Oral administration.
• Combination potential with ezetimibe.
• Cardiovascular-outcome data in statin-intolerant patients.
• Later-expiring formulation and method-of-use claims.

The main vulnerability is the availability of prior-art arguments against broad composition or use claims. Combination and formulation patents may withstand some challenges but provide narrower protection than a valid composition patent.

What is the Orange Book status of hypolipidemic drugs?

The FDA Orange Book lists approved small-molecule products and patents submitted by sponsors. It does not list biologic reference products in the same manner. Biologic reference products and biosimilar competition are addressed through the Purple Book.

Product	FDA patent listing framework	Generic or biosimilar pathway
Nexletol	Orange Book	ANDA with Paragraph IV certification
Nexlizet	Orange Book	ANDA with Paragraph IV certification
Vascepa	Orange Book	ANDA; extensive prior litigation
Zetia	Orange Book	ANDA; generic entry occurred
Repatha	Biologic framework	Biosimilar application under the PHS Act
Praluent	Biologic framework	Biosimilar application under the PHS Act
Leqvio	Biologic framework	Biosimilar-like follow-on competition, subject to FDA pathway

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. A timely notice can trigger a 30-month stay of ANDA approval under the Hatch-Waxman Act, subject to statutory exceptions and court developments.[7]

Which companies are challenging branded hypolipidemic products?

Generic and biosimilar companies that commonly participate in this market include Teva, Mylan/Viatris, Sandoz, Dr. Reddy’s Laboratories, Zydus, Amneal, Sun Pharma, Lupin, and Hikma. The specific challenger depends on product, jurisdiction, and filing date.

Vascepa illustrates the litigation exposure of small-molecule lipid products. Amarin litigated patents covering icosapent ethyl and cardiovascular-risk reduction against generic applicants. Federal appellate decisions narrowed the enforceability of certain patents, and generic competition materially affected the product’s revenue trajectory.[8]

For newer products, likely challengers will target:

• Broad composition claims.
• Obviousness of combination therapy.
• Written-description and enablement issues.
• Clinical-outcome method claims.
• Formulation claims lacking unexpected results.
• Orange Book listing accuracy and improper patent delisting.

What patent litigation affects hypolipidemic agents?

The most commercially relevant disputes fall into four groups.

PCSK9 antibody litigation

Amgen and Sanofi/Regeneron have litigated antibody patents involving PCSK9 binding and therapeutic use. These cases established that competing biologics can face overlapping patent estates even when the molecules are independently developed.

Icosapent ethyl litigation

Amarin’s Vascepa litigation involved patents covering purified EPA compositions and cardiovascular-risk reduction. Generic applicants challenged the patents through Paragraph IV certifications. The resulting appellate decisions weakened Amarin’s ability to block generic entry.[8]

Statin and ezetimibe litigation

The core statin and ezetimibe markets are largely generic. Remaining disputes typically concern:

• Combination products.
• Pediatric or secondary indications.
• Formulation claims.
• Authorized-generic arrangements.
• Manufacturing patents outside the United States.

Bempedoic-acid litigation

Bempedoic acid has the most significant future small-molecule patent exposure among newer oral LDL-lowering products. Paragraph IV litigation could determine whether generic entry occurs before 2040 or is delayed by later-issued patents and settlement terms.

What generic launch scenarios exist for hypolipidemic drugs?

Scenario	Products most exposed	Market consequence
First-filer 180-day generic competition	Nexletol, Nexlizet, Vascepa-type products	Temporary high-value generic exclusivity
Multiple generic entry	Statins, ezetimibe, fibrates	Rapid price erosion
Authorized generic	Products with settlement or originator supply agreements	Lower litigation risk, controlled erosion
At-risk launch	Products with unresolved patent litigation	Damages exposure and possible injunction
Biosimilar entry	Repatha and Praluent	Gradual uptake; interchangeability and payer policy matter
Follow-on oligonucleotide entry	Leqvio	High technical and regulatory barriers

Generic statins can lose most branded revenue quickly after approval of the first ANDA. Injectable biologics usually decline more slowly because physician prescribing, payer contracts, supply-chain controls, and interchangeability affect uptake.

What regulatory exclusivity remains for hypolipidemic drugs?

Small-molecule products receive five years of new chemical entity exclusivity when eligible, with three-year exclusivity for certain new clinical investigations. Orphan-drug exclusivity can add seven years for qualifying indications. Pediatric exclusivity can add six months to existing patent or regulatory protection.[7]

Biologic reference products receive 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, but this period does not automatically prevent biosimilar filing after four years. Patent disputes determine the practical launch date.[5]

Inclisiran and PCSK9 antibodies benefit from biologic regulatory protection. Bempedoic acid depends on small-molecule exclusivity and patents. Statins, ezetimibe, and most fibrates have exhausted regulatory exclusivity.

What manufacturing and intellectual-property barriers affect this market?

Manufacturing barriers are material for injectable and advanced therapies.

Monoclonal antibodies

PCSK9 antibodies require validated mammalian-cell production, purification, viral clearance, sterility controls, and device compatibility. Biosimilar applicants must demonstrate high similarity and address immunogenicity and pharmacokinetic comparability.

Inclisiran

Inclisiran requires controlled oligonucleotide synthesis, sequence fidelity, chemical modification, GalNAc conjugation, impurity removal, and long-term stability. These steps can create process patents that remain relevant after composition patents expire.

Bempedoic acid

The manufacturing process is less complex than for biologics or siRNA. The strongest barriers are therefore likely to be patent-based rather than process-based, particularly for combination products and cardiovascular-risk-reduction claims.

Icosapent ethyl

Purity, oxidation control, capsule formulation, and analytical characterization influence product quality. These factors can support regulatory differentiation but do not necessarily prevent generic competition once core patents fail.

How does the hypolipidemic patent landscape vary geographically?

The United States is the highest-value jurisdiction because of pricing, Orange Book litigation, and the Hatch-Waxman framework. Europe generally experiences earlier price compression through centralized or coordinated national reimbursement systems, even when patents remain in force.

Region	Principal protection mechanism	Commercial implication
United States	Patents, Orange Book, Purple Book, Hatch-Waxman, BPCIA	Highest litigation intensity and launch value
European Union	European patents, Supplementary Protection Certificates, national reimbursement	Patent term matters, but price erosion is often faster
Japan	Patents, patent-term extensions, national reimbursement	Regulatory and pricing review affects launch economics
China	Chinese patents, regulatory exclusivity, centralized procurement	Rapid price pressure after local competition
Canada	Patents, PM(NOC) regulations	Litigation can delay generic entry
Emerging markets	National patents and local registration rules	Patent enforcement and pricing vary sharply

Supplementary Protection Certificates may extend protection for European products that lost time during regulatory development. In the United States, patent-term adjustment, patent-term extension, pediatric exclusivity, and litigation stays can materially change effective entry dates.

How does the hypolipidemic market compare with other cardiovascular drug classes?

Class	Generic pressure	Innovation activity	Patent durability
Statins	Very high	Low for new molecules	Low
Ezetimibe	High	Combination-focused	Low to moderate
PCSK9 antibodies	Low at present	Moderate	High
Inclisiran	None established	High	High
Bempedoic acid	None established at scale	Moderate	Moderate to high
Fibrates	Very high	Low	Low
Omega-3 products	Mixed	Moderate	Product-specific

The most defensible future revenue streams are therapies with durable delivery or manufacturing barriers. The highest pricing risk remains with products whose value proposition depends mainly on LDL reduction without strong outcomes evidence, because payers can substitute lower-cost statins and ezetimibe.

What is the outlook for licensing deals and business development?

The sector has favored transactions involving differentiated mechanisms, cardiovascular-outcome evidence, and delivery advantages. The Novartis acquisition of The Medicines Company’s inclisiran program is the clearest example. Large companies have also used co-development, regional commercialization, and royalty structures to access lipid-lowering assets without building all discovery capabilities internally.[6]

Potential licensing value is highest for:

• Long-acting injectable therapies.
• Oral agents for statin-intolerant patients.
• Combination products that improve adherence.
• Therapies targeting lipoprotein(a), triglyceride-rich lipoproteins, or remnant cholesterol.
• Manufacturing platforms for siRNA and other nucleic-acid medicines.

A licensee will typically evaluate patent term, freedom to operate, clinical-outcome support, payer restrictions, and the probability of Paragraph IV or biosimilar litigation.

Key Takeaways

• Statins and ezetimibe dominate volume but are largely generic.
• Repatha and Praluent face future biosimilar competition, with patent estates likely to determine practical entry.
• Leqvio has a longer-duration commercial model and a complex siRNA, conjugation, formulation, and manufacturing estate.
• Bempedoic acid has the strongest near- and medium-term small-molecule patent value among newer oral LDL-lowering products.
• Vascepa demonstrates the revenue impact of adverse patent litigation and generic launch.
• Orange Book litigation controls small-molecule generic entry; the Purple Book and BPCIA framework control biologic follow-on competition.
• Manufacturing complexity is a meaningful barrier for antibodies and inclisiran but less so for oral small molecules.
• United States patent outcomes have the greatest effect on global asset value, while European and emerging-market price systems accelerate post-entry erosion.

FAQs

Are PCSK9 inhibitors protected by patents or biologic exclusivity?

They are protected by both biologic regulatory exclusivity and patents covering antibodies, binding regions, formulations, dosing, and manufacturing. Patents generally determine the practical biosimilar launch date.

Can a generic company file an ANDA for Leqvio?

Leqvio is a biologic product, so conventional ANDA approval is generally not the applicable pathway. A follow-on applicant would need to use the biologic regulatory framework or another FDA pathway permitted for the product’s classification.

Which hypolipidemic drug has the highest Paragraph IV risk?

Bempedoic-acid products and newer omega-3 products have the most relevant small-molecule Paragraph IV exposure. The risk depends on listed patents, claim breadth, and the timing of ANDA filings.

Do statin patents still have commercial value?

Core statin patents have expired in major markets. Residual value may exist in fixed-dose combinations, pediatric formulations, manufacturing processes, or jurisdiction-specific secondary patents.

Is inclisiran more difficult to copy than a PCSK9 antibody?

Inclisiran presents distinct technical barriers involving oligonucleotide synthesis, chemical modification, GalNAc conjugation, impurity control, and long-term stability. Those barriers can make follow-on development more complex, although they do not eliminate patent challenges.

References

1. Amgen Inc. (2024). 2023 annual report.
2. Novartis AG. (2024). 2023 annual report.
3. Esperion Therapeutics, Inc. (2024). 2023 annual report.
4. Amarin Corporation plc. (2024). 2023 annual report.
5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
6. Novartis AG. (2019). Novartis to acquire The Medicines Company, adding inclisiran, a first-in-class investigational siRNA cholesterol-lowering therapy.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
8. United States Court of Appeals for the Federal Circuit. (2020). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 923 F.3d 1033.